Good for Business, Investments, Lithuania, Technology, USA

CasZyme CEO Monika Kavaliauske told the business daily that a contract had been signed with DowDuPont to allow developing operations based on DowDuPont intellectual property and CasZyme know-how and experience. Nevertheless, she did not rule out that additional partners could be invited in the future along with risk capital investments for development of the company's other operations. Kavaliauske did not disclose the size of the stake transferred to the DowDuPont concern.

The CasZyme CEO said the company would mainly focus on development of new molecular tools and provide research services for businesses, other researchers and organizations, as well as continue developing the CRISPR technology y and searching for new Cas proteins that could be used as new-generation molecular tools for genome editing. In Kavaliauske's words, the operations would not be limited to agricultural and crop production research, and the Lithuanian company will not develop pharmaceutical products.